Kurs gut hingepackt LIXTE BIOTECHNOLOGY INC Aktie ,GrB
Top-News
LIXTE hübsches Ding
Beiträge:
24
Zugriffe: 6.179 / Heute: 2
Zugriffe: 6.179 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von SPDR
SPDR MSCI World Communication Services UCITS ETF
Perf. 12M: +46,80%
SPDR S&P U.S. Communication Serv. Select Sector UCITS ETF Ac
Perf. 12M: +44,22%
SPDR MSCI World Technology UCITS ETF
Perf. 12M: +42,72%
SPDR S&P U.S. Financials Select Sector UCITS ETF
Perf. 12M: +42,42%
SPDR S&P U.S. Consumer Discretionary Select Sector UCITS ETF
Perf. 12M: +40,85%
Zeit Kurs Stück
18:15:09 0,2565 $ 2.400
so funzt das ,GrB
18:15:09 0,2565 $ 2.400
so funzt das ,GrB
ISIN: US5393191037Symbol: LIXTTyp: Aktie SKP +2,60% Pott +2,60% buran
0,30 $ +16,95% +0,0435 $
In Euro: 0,2253 € | Nasdaq OTC Other, 17.01.13
thread Pott somit auf +20,00% erhöht
In Euro: 0,2253 € | Nasdaq OTC Other, 17.01.13
thread Pott somit auf +20,00% erhöht
0,74 $ +63,53% +0,2875 $
dann klappt's auch mit der Nachbarin
dann klappt's auch mit der Nachbarin
Materials Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke
15:05 10.12.13
PR Newswire
EAST SETAUKET, N.Y., Dec. 10, 2013
EAST SETAUKET, N.Y., Dec. 10, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTC: LIXT), a clinical-stage pharmaceutical company, has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Dr. John Kovach, the founder of Lixte said "Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety of compounds proprietary to Lixte. This research will examine the compounds' potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases."
"Under an M-CRADA, a party provides research material, in this case proprietary compounds from Lixte's pipeline, for study by scientists at NIH. The exchange of materials is for research only and implies no endorsement of the materials on the part of either party." Dr. Kovach continued, "Lixte's primary emphasis is on developing drugs for the treatment of cancer but its compounds also have potential for treating a variety of other diseases and we welcome exploration of these possibilities by NIH scientists." Dr. Kovach noted that part of the appeal of an M-CRADA for a company is that "NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive commercialization license." He adds, "As Lixte is eager to bring new potentially more-effective compounds for the treatment of human diseases to the clinic as rapidly as possible, the company encourages outstanding investigators such as those at NINDS to undertake studies of its compounds."
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. For further discussion of the Lixte pipeline, go to:
lixte.com/Nature_Biotechnology_2013_Lixte_Ad.pdf
Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10Q for September 30, 2013.
For additional information, please see: www.lixte.com
SOURCE Lixte
Quelle: PR Newswire
15:05 10.12.13
PR Newswire
EAST SETAUKET, N.Y., Dec. 10, 2013
EAST SETAUKET, N.Y., Dec. 10, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (OTC: LIXT), a clinical-stage pharmaceutical company, has signed a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS, NIH). Dr. John Kovach, the founder of Lixte said "Under this agreement, the Surgical Neurology Branch of NINDS, NIH, will conduct research characterizing a variety of compounds proprietary to Lixte. This research will examine the compounds' potential for anti-cancer activity, reducing neurological deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases."
"Under an M-CRADA, a party provides research material, in this case proprietary compounds from Lixte's pipeline, for study by scientists at NIH. The exchange of materials is for research only and implies no endorsement of the materials on the part of either party." Dr. Kovach continued, "Lixte's primary emphasis is on developing drugs for the treatment of cancer but its compounds also have potential for treating a variety of other diseases and we welcome exploration of these possibilities by NIH scientists." Dr. Kovach noted that part of the appeal of an M-CRADA for a company is that "NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive commercialization license." He adds, "As Lixte is eager to bring new potentially more-effective compounds for the treatment of human diseases to the clinic as rapidly as possible, the company encourages outstanding investigators such as those at NINDS to undertake studies of its compounds."
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company, using biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. For further discussion of the Lixte pipeline, go to:
lixte.com/Nature_Biotechnology_2013_Lixte_Ad.pdf
Forward-Looking Statements
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10Q for September 30, 2013.
For additional information, please see: www.lixte.com
SOURCE Lixte
Quelle: PR Newswire
Dr. Daniel Von Hoff Joins Lixte Biotechnology's Scientific Advisory Board
15:05 07.01.14
PR Newswire
EAST SETAUKET, N.Y., Jan. 7, 2014
EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board.
"We are extremely pleased that Dr. Von Hoff has joined the Lixte Scientific Advisory Board. Dr. Von Hoff is internationally recognized as a leader in the pre-clinical and clinical development of new anti-cancer drugs. He and his colleagues were instrumental in the advancement of many anti-cancer drugs now used routinely in cancer care. We very much look forward to Dr. Von Hoff's suggestions regarding the most efficient clinical development of our proprietary anti-cancer compounds," says Dr. Kovach.
Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute), Phoenix, AZ. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute and holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
Dr. Von Hoff served on the National Cancer Advisory Board from 2004-2010. He is a past President of the American Association of Cancer Research (AACR), Fellow of the American College of Physicians (FACP), and a member and past board member of the American Society of Clinical Oncology (ASCO). He is a founder of ILEX™Oncology, Inc., subsequently acquired by Genzyme. Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs: The Journal of New Anti-Cancer Agents and Editor-in-Chief of Molecular Cancer Therapeutics.
Dr. Von Hoff has published more than 600 papers and 135 book chapters. He received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care.
For additional information, please see: www.lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.
Quelle: PR Newswire
15:05 07.01.14
PR Newswire
EAST SETAUKET, N.Y., Jan. 7, 2014
EAST SETAUKET, N.Y., Jan. 7, 2014 /PRNewswire/ -- John S. Kovach, M.D., President and CEO, Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces the appointment of Daniel D. Von Hoff, MD, FACP, to the company's Scientific Advisory Board.
"We are extremely pleased that Dr. Von Hoff has joined the Lixte Scientific Advisory Board. Dr. Von Hoff is internationally recognized as a leader in the pre-clinical and clinical development of new anti-cancer drugs. He and his colleagues were instrumental in the advancement of many anti-cancer drugs now used routinely in cancer care. We very much look forward to Dr. Von Hoff's suggestions regarding the most efficient clinical development of our proprietary anti-cancer compounds," says Dr. Kovach.
Dr. Von Hoff is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute), Phoenix, AZ. He is also Chief Scientific Officer for US Oncology and for Scottsdale Healthcare's Clinical Research Institute and holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.
Dr. Von Hoff served on the National Cancer Advisory Board from 2004-2010. He is a past President of the American Association of Cancer Research (AACR), Fellow of the American College of Physicians (FACP), and a member and past board member of the American Society of Clinical Oncology (ASCO). He is a founder of ILEX™Oncology, Inc., subsequently acquired by Genzyme. Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs: The Journal of New Anti-Cancer Agents and Editor-in-Chief of Molecular Cancer Therapeutics.
Dr. Von Hoff has published more than 600 papers and 135 book chapters. He received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care.
For additional information, please see: www.lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.
Quelle: PR Newswire
Datum Erster Hoch Tief Schluss Stücke Volumen
31.12.13 0,13 0,13§0,13 0,13 $ 7.060 918
23.12.13 0,16 0,16§0,13 0,13 $ 21.400 3.148
17.12.13 0,20 0,20§0,20 0,20 $ 5.000 1.000
04.12.13 0,21 0,21§0,21 0,21 $ 7.500 1.575
02.12.13 0,21 0,21§0,21 0,21 $ 2.500 525
GrB
31.12.13 0,13 0,13§0,13 0,13 $ 7.060 918
23.12.13 0,16 0,16§0,13 0,13 $ 21.400 3.148
17.12.13 0,20 0,20§0,20 0,20 $ 5.000 1.000
04.12.13 0,21 0,21§0,21 0,21 $ 7.500 1.575
02.12.13 0,21 0,21§0,21 0,21 $ 2.500 525
GrB
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Annual Report on Form 10Q for September 30, 2013.
For additional information, please see: www.lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.
Quelle: PR Newswire
For additional information, please see: www.lixte.com
SOURCE Lixte Biotechnology Holdings, Inc.
Quelle: PR Newswire
Datum Erster Hoch Tief Schluss Stücke Volumen
16.01.14 0,20 0,20§0,20 0,20 $ 1.000 200
13.01.14 0,21 0,21§0,21 0,21 $ 5.000 1.050
02.01.14 0,20 0,20§0,20 0,20 $ 15.000 3.000
GrB
16.01.14 0,20 0,20§0,20 0,20 $ 1.000 200
13.01.14 0,21 0,21§0,21 0,21 $ 5.000 1.050
02.01.14 0,20 0,20§0,20 0,20 $ 15.000 3.000
GrB
technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte's product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development which the company believes have broad therapeutic potential not only for cancer but for other debilitating and life-threatening diseases. Lixte's unique phosphatase inhibitor, LB-100, is in a Phase I cancer trial at two NCI designated Comprehensive Cancer Centers (see ClinicalTrials.gov: Identifier NCTO1837667). For further discussion of the Lixte pipeline, go to: lixte.com/Nature_Biotechnology_2013_Lixte_Ad.pdf
::::::::::::::: 0,15 $ +50,00% +0,05 $
In Euro: 0,1183 € | Nasdaq OTC Other, 15.10.14:::::: DOCH
In Euro: 0,1183 € | Nasdaq OTC Other, 15.10.14:::::: DOCH
Ein Unternehmen hat genügend freie Finanzmittel zur Verfügung und eine Liquidität ("Flüssigkeit") ist somit gewährleistet. Anders im Falle der Illiquidität: keine Mittel sind kurzfristig frei. http://www.ariva.de/extras/lexikon.m?begriff=Liquiditaet
::::::::::::::: 0,25 $ +25,00% +0,05 $
In Euro: 0,2203 € | Nasdaq OTC Other, 13.02.15 ,GrB
In Euro: 0,2203 € | Nasdaq OTC Other, 13.02.15 ,GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
20.03.15 0,29 0,29§0,241 0,25 $ 32.700 8.363
GrB
20.03.15 0,29 0,29§0,241 0,25 $ 32.700 8.363
GrB
NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Rekordjagd wieder aufgenommen. Unerwartet starke Quartalszahlen des weltgrößten Sportartikelkonzerns Nike, ein nachgebender US-Dollar sowie deutlich anziehende Ölpreise hätten die Kurse gestützt, hieß es. Für Bewegung sorgte auch der vierteljährliche "Hexensabbat": An diesem Freitag liefen an den Terminbörsen zahlreiche Wetten auf Aktienkurse und Indexstände aus. http://www.ariva.de/news/...r-auf-Rekordjagd-Wochenplus-gut-2-5316781
Prozent auf 18 127,72 Punkte und steht damit nur noch ein knappes Prozent unter seinem bisherigen Rekordhoch von Anfang März. Das Wochenplus beläuft sich auf gut 2 Prozent. Der marktbreite S&P-500-Index rückte am Freitag um 0,90 Prozent auf 2108,08 Punkte vor. Der technologielastige Auswahlindex Nasdaq 100 (Nasdaq 100) stieg um 0,72 Prozent auf 4458,54 Zähler. Der Nasdaq Composite kletterte im Verlauf bis auf 5042 Punkte und damit auf den höchsten Stand seit 15 Jahren. Am Ende blieb noch ein Plus von 0,68 Prozent bei 5026,42 Punkten. http://www.ariva.de/news/...r-auf-Rekordjagd-Wochenplus-gut-2-5316781
buran
buran
22:34 01.04.15
NEW YORK (dpa-AFX) - Enttäuschende Konjunkturdaten haben den US-Anlegern am Mittwoch den Quartalsstart verhagelt. Die wichtigsten Aktienindizes weiteten ihre Vortagesverluste etwas aus. Börsianer stellten vor allem auf aktuelle Jobdaten des Dienstleisters ADP ab, die auf die Stimmung gedrückt hätten. Demnach hatte die Zahl der neu geschaffenen Stellen im Privatsektor im März mit 189 000 deutlich unter den im Schnitt von Volkswirten erwarteten 225 000 neuen Jobs gelegen. Zudem hatte sich im März die Stimmung in der US-Industrie überraschend weiter eingetrübt und den tiefsten Stand seit fast zwei Jahren erreicht. http://www.ariva.de/news/...uer-enttaeuschenden-Quartalsstart-5327839
NEW YORK (dpa-AFX) - Enttäuschende Konjunkturdaten haben den US-Anlegern am Mittwoch den Quartalsstart verhagelt. Die wichtigsten Aktienindizes weiteten ihre Vortagesverluste etwas aus. Börsianer stellten vor allem auf aktuelle Jobdaten des Dienstleisters ADP ab, die auf die Stimmung gedrückt hätten. Demnach hatte die Zahl der neu geschaffenen Stellen im Privatsektor im März mit 189 000 deutlich unter den im Schnitt von Volkswirten erwarteten 225 000 neuen Jobs gelegen. Zudem hatte sich im März die Stimmung in der US-Industrie überraschend weiter eingetrübt und den tiefsten Stand seit fast zwei Jahren erreicht. http://www.ariva.de/news/...uer-enttaeuschenden-Quartalsstart-5327839
Nicht mal die deutsche Rechtschreibung beherrscht das BURAN'sche ...
..yöah
..yöah
Zeit Kurs Stück
18:21:26§0,26 $ 17.900
18:21:23§0,238 $ 2.100
_____________________
GRATULATION
18:21:26§0,26 $ 17.900
18:21:23§0,238 $ 2.100
_____________________
GRATULATION
::::::::: 0,3114 $ +24,56% +0,0614 $
In Euro: 0,2816 € | 06.07.16 Nasdaq OTC Other ,GrB
In Euro: 0,2816 € | 06.07.16 Nasdaq OTC Other ,GrB
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem Lixte Biotechnology Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 23 | LIXTE hübsches Ding | buran | buran | 25.04.21 00:59 |
